Geoffrey Beran Rose - 01 Mar 2023 Form 4 Insider Report for Pulmonx Corp (LUNG)

Role
Chief Commercial Officer
Signature
/s/ Lauren Cristina, Attorney-in-Fact for Geoffrey Beran Rose
Issuer symbol
LUNG
Transactions as of
01 Mar 2023
Net transactions value
-$13,302
Form type
4
Filing time
03 Mar 2023, 18:02:43 UTC
Previous filing
05 Dec 2022
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUNG Common Stock Sale $4,820 -437 -0.24% $11.03 181,762 01 Mar 2023 Direct F1, F2
transaction LUNG Common Stock Sale $8,482 -769 -0.42% $11.03 180,993 01 Mar 2023 Direct F3
transaction LUNG Common Stock Award $0 +78,900 +44% $0.000000 259,893 01 Mar 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LUNG Employee Stock Option (right to buy) Award $0 +54,000 $0.000000 54,000 01 Mar 2023 Common Stock 54,000 $11.48 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021.
F2 Includes 1,162 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on February 15, 2023.
F3 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 1, 2022.
F4 Represents grant of Restricted Stock Units payable solely in common stock of the Issuer that vest over four years in equal quarterly installments beginning on March 1, 2023.
F5 The shares subject to the option vest in 48 equal monthly installments beginning on March 1, 2023.